Dr. Srinivasan on VHL-associated RCC prognosis and treatment
Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.
Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, provides in-depth background of the prognosis and treatment development for Von Hippel-Lindau (VHL)–associated renal cell carcinoma (RCC).
During the 2020 Society of Urologic Oncology Annual Meeting, Srinivasan shared results from a phase 2 study of the investigational HIF-2α inhibitor MK-6482 in patients with VHL–associated RCC. At a median follow-up of 68.7 weeks (range, 18.3-104.7), the objective response rate in RCC lesions among 60 evaluable patients was 36.1%, comprising 22 confirmed partial responses. There were also 7 unconfirmed PRs. Overall, 91.8% (n = 56) of patients had at least some decrease in the size of target lesions.
Mitochondrial metabolism may promote kidney cancer metastasis, new data show
August 14th 2024“The challenge now is to understand how these key aspects of mitochondrial metabolism become activated, why they stimulate metastasis, and whether we can safely block them,” says Ralph J. DeBerardinis, MD, PhD.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
